Vascular conduits used during most vascular surgeries are allogeneic or synthetic grafts that often lead to complications caused by immunosuppression and poor patency. Tissue engineering offers a novel solution to generate personalized grafts with a natural extracellular matrix containing the recipient's cells using the method of decellularization and recellularization. We show a detailed method for performing decellularization of the human saphenous vein and recellularization by perfusion of peripheral blood. The vein was decellularized by perfusing 1% Triton X-100, 1% tri-n-butyl-phosphate (TnBP) and 2,000 Kunitz units of deoxyribonuclease (DNase). Triton X-100 and TnBP were perfused at 35 mL/min for 4 h while DNase was perfused at 10 mL/min at 37 °C for 4 h. The vein was washed in ultrapure water and PBS and then sterilized in 0.1% peracetic acid. It was washed again in PBS and preconditioned in endothelial medium. The vein was connected to a bioreactor and perfused with endothelial medium containing 50 IU/mL heparin for 1 h. Recellularization was performed by filling the bioreactor with fresh blood, diluted 1:1 in Steen solution, and adding endocrine gland-derived vascular endothelial growth factors (80 ng/mL), basic fibroblast growth factors (4 µL/mL), and acetyl salicylic acid (5 µg/mL). The bioreactor was then moved into an incubator and perfused for 48 h at 2 mL/min while maintaining glucose between 3 -9 mmol/L. Later, the vein was washed with PBS, filled with endothelial medium and perfused for 96 h in the incubator. Treatment with Triton X-100, TnBP and DNase decellularized the saphenous vein in 5 cycles. The decellularized vein looked white in contrast to normal and recellularized veins (light red). The hematoxylin & eosin (H&E) staining showed the presence of nuclei only in normal but not in decellularized veins. In the recellularized vein, H&E-staining showed the presence of cells on the luminal surface of the vein.
Introduction
Vascular conduits are required for several clinical conditions like aneurysms, carotid artery stenosis and atherosclerosis leading to severe vascular problems. Surgeons use autologous, allogeneic or synthetic vascular conduits to restore the functional blood supply. Although the use of autologous blood vessels is still considered the ideal approach, the availability in patients is majorly limited. The alternatives such as allogeneic or synthetic grafts have profound problems with immunosuppressive treatments and poor patency leading to reoperation 1, 2 , resulting in major health economic burdens to countries. Tissue engineering of blood vessels aims to provide grafts with a natural homology and autologous cells. Thus, the recipient immune system recognizes the transplanted graft as the self and since such a graft contains the natural proteins and cells in the original configuration, it might function better in comparison to the current alternatives. Tissue engineered organs, such as the bladder 3 , the urethra 4 , the trachea 5 , and veins 6, 7 , have been successfully used in the clinic.
Tissue engineering to produce personalized grafts requires a graft from a donor followed by decellularization and recellularization. Decellularization is a promising technology to remove cells from tissues and organs 8, 9, 10 . Decellularization can be performed by specific physical, chemical and enzymatic methods 11 or by combining them. At optimal usage of these methods, decellularized tissues can have similar structural and functional proteins in an extracellular matrix similar to native tissues. Such organs possess the intrinsic capacity to enhance attachment, migration, proliferation, and differentiation of incoming stem cells.
Recellularization is a dynamic process of seeding cells into the graft, and recipient stem cells can be used for clinical transplantation. Stem cells currently used for such purposes include bone marrow, mesenchymal and organ residents 3, 5, 6 . Animal and research-oriented studies have used stem cells from mesenchymal origins that are fetal and induced pluripotent 12, 13, 14 . This process requires a bioreactor (a chamber that holds the vein and provides the necessary conditions like temperature, gases, pH, and pressure), cells and culture media. The challenge in recellularization is to obtain the required number of cells of a particular type and a seeding strategy by which cells can reach whole tissue or organ. Even though no complete tissue or organ structurally and functionally has been generated and evaluated until now, several advancements in the field and initial results show the future possibility . Studies have demonstrated that during damage, endothelialization occurs either from anastomosis or from circulating endothelial progenitor cells (EPCs) in blood 17, 18, 19 . Our strategy for recellularization of veins relies on the EPCs present in circulating blood.
Tissue engineering of veins and arteries was performed by several groups following different decellularization and recellularization strategies 20, 21 . Our group has also performed and developed decellularization and recellularization strategies for iliac and mammary veins 6, 7 . Decellularization was performed by agitation of the vein in Triton X-100, tri-n-butyl phosphate (TnBP), and enzyme deoxyribonuclease (DNase). The recellularization was performed using either bone marrow derived endothelial and smooth muscle cells 6 or peripheral blood 7 . The veins recellularized by either protocol showed clinical promise in providing functional blood supply in transplantation of pediatric patients with extra hepatic portal vein obstruction 6, 7 .
We have currently developed a modified version of the same protocol for the improved and easy performance of decellularization, recellularization and bioreactor handling of small diameter veins. The current decellularization protocol required perfusion of detergents through the vein using pressure instead of agitation with detergents. The recellularization protocol involves an additional step of preconditioning for improving cell adhesion and the addition of growth factors in circulating blood for improving cell adhesion, survival and proliferation. We have also improved the design of the bioreactor using commercially available products. In this paper, we present a detailed description of the modified protocol for performing decellularization and recellularization of human saphenous veins.
Protocol
The tissue used, and the protocol of this paper follows the ethical guidelines of Gothenburg University. 
Tissue Preparation and Storage

Preparation of Decellularization Setups and Recellularization Bioreactor
NOTE: Using scissors, cut the silicon tubes as shown in Table 1 .
1. Decellularization Setup 1 (For Triton X-100 perfusion and washing) 1. To a 2 L chamber (plastic tub), tape all three pieces of tube A as shown in Figure 1A . NOTE: Tape one tube to one wall where the edge touches the bottom of the chamber (detergent's inlet) and the other two tubes to the opposite wall with a distance of 5 -10 cm in between depending on the length of the vein. At least 5 cm of these tubes should also be taped to the chamber's floor (vein's inlet and outlet). 2. Using the male and female Luer connectors, connect in series the detergent's inlet tube to tube B followed by tube F, tube C and finally to the vein inlet. Place the tube F into the cassette of the peristaltic pump I. 3. Take another tube C and connect one end to the vein's outlet. Place the other end into the glass jar with the bottom hose outlet that is placed 45 cm above the chamber (detergent outlet) and tape it to secure. Take tube G and push one end into the hose outlet of the glass jar and place the other end into the vein chamber. NOTE: The pictures of complete setup (red arrows), chamber, and flow direction (white arrows) are shown in Figure 1A .
Decellularization Setup 2 (For TnBP perfusion)
1. Take a 1 L glass jar, and place one end of tube C (detergent inlet) into the jar until the tube touches the jar's bottom. 2. Connect the other end to tube F followed by tube C. Place the other end of tube C into the jar until half depth (vein's inlet). Place tube F into the cassette of peristaltic pump I. 3. Take tube D and place one end into the jar (vein's outlet) until half depth and the other end into the glass jar with the bottom hose placed at a 45 cm height from the vein's inlet (detergent outlet). To secure, tape the detergent's inlet and outlet tubes. 4. Place the 1 L glass jar on a magnetic stirrer and keep the magnet inside the bottle. 5. Take tube G and push one end onto the hose outlet of the glass jar and place the other end into 1 L glass jar.
NOTE: The picture of complete setup (red arrows), chamber and flow direction (white arrows) is shown in Figure 1B .
Decellularization Setup 3 (For DNase perfusion)
1. Take a 250 mL glass bottle and place both ends of tube C. Place the middle area of the tube into the cassette of peristaltic pump II. NOTE: One end of the tube is the solution inlet and the other end of the tube is connected to the vein's inlet. The vein's outlet is left free in solution. 2. Place the whole setup including pump at 37 °C. The picture of complete setup and flow direction is shown in Figure 1C .
Recellularization Bioreactor
1. Keep ready all the parts as shown in Figure 2A . Figure 2B , take the 4-port cap and insert into each port, tube H (vein's outlet), tube I (media inlet), and tube J (vein's inlet).
As shown in
Insert the other end of tube H into the 4 th port (media outlet).
NOTE: The view of the 4-port cap from the top is shown in Figure 2C . For easy insertion of tubes, cut the edges to a sharp point with a scissor. 3. Bend the other end of tube J into a U shape and tie it with a suture. Connect the reducing connectors to the inner ends of tubes H & J.
4. Place the 60 mL tube with a flat base into the 250 mL glass bottle and then place the above made setup into the tube as shown in Figure 2D . As shown in Figure 2E , connect tubes K, E, and K in series. Connect one tube K to the vein's inlet and another tube K to the media inlet. NOTE: The schematic diagram of the setup, and flow direction is seen in Figure 2F . 5. Sterilize the bioreactor by autoclaving. 
Preparation of Solutions
Preparation of Endothelial Medium
1. Add 5 mL of L-glutamine, 5 mL of anti-anti, 50 mL of human AB serum and all components of EGM-2 growth factor kit except fetal bovine serum to 500 mL of the MCDB131 medium under a sterile hood. 
Decellularization of Saphenous Vein
Verification of Decellularization
Recellularization
1. Sterilize the vein by placing it in a 50 mL tube containing 50 mL of solution 8. Agitate at 80 rotations per minute (rpm) in the shaker for 1 h at 37 °C. 2. Handle the vein under the laminar flow (LAF) cabinet from now on to maintain sterility. Transfer the vein using sterile forceps to a new 50 mL tube containing 50 mL of sterile solution 7 and 500 µL of anti-anti. Agitate as above for 12 h. Change Solution 7 at least twice in between. 3. Using sterile forceps, transfer the vein to a new 50 mL tube and add 50 mL of endothelial media. Agitate as above for 11 h. 4. Assemble the bioreactor using sterile gloves under the LAF cabinet. Tie the vein to the bioreactor's vein inlet and outlet with sterile suture and forceps. 5. Connect the vein to the bioreactor and fill with the same medium. Add heparin at 50 IU/mL and perfuse for 1 h at 2 mL/min in 37 °C.
Discussion
The technique presented here for decellularization of saphenous veins is an easy, simple and cost-effective method that can also be applied to all small diameter veins like umbilical and mammary veins. The decellularization solutions and their concentrations used in this method are from our previous results 6, 7 . Even though we recommend 5 cycles of decellularization, in certain veins we also noticed complete decellularization in 3 cycles. However, reproducible results were obtained by using 5 cycles. Applying this protocol, we decellularized veins of varying lengths up to 30 cm successfully (unpublished result). Lifting the decellularization solution's outlet by 45 cm will create a pressure of 33 mmHg inside the vein. In our experience, we noticed this as a key step in decellularizing the whole vein uniformly and reproducibly in 5 cycles. The chosen pressure is 3 times higher than the normal saphenous vein pressure (5 -10 mmHg) but is the same as in incompetent veins (varicose veins) 23 . In addition, we speculate that this high pressure will create a significant force on vein walls and may, therefore, aid in efficient and faster cell removal.
Since TnBP is an organic solvent and insoluble in water, stirring the detergent until it becomes cloudy is important; otherwise, the detergent will float. For the same reason, to keep TnBP mixed in solution, the detergent's outlet tube was placed at the top of the glass jar with the hose outlet. Efficient removal of TnBP from the vein after its usage in every cycle can be seen by the absence of floating TnBP droplets in the washed water. We have also noticed that skipping the DNase step also produced a decellularized tissue but in a few cases, a comparatively high DNA content in the decellularized tissue was noticed. As high pressure and high flow rates are not required for efficient DNase activity, a low perfusion rate (10 mL/min) may be used. A different peristaltic pump was used as its smaller size helps in easy handling of the setup. Since we noticed that damage of most cells during decellularization results in cycle 2, we suggest skipping DNase treatment during cycles 1 and 3 (unpublished result). Even though the characterization and quantification of extracellular matrix proteins were not performed in this manuscript, our previous experience with similar decellularization protocols showed the preservation of biomechanical properties, extracellular matrix structure and proteins 7 . Though our preliminary quantification experiments with these veins produced a similar result (unpublished), our already published results will strengthen this confidence.
Recellularization using blood is a convenient and easy process over bone marrow expanded cells as one can avoid long cell expansion times, spontaneous mutations in expanded cells, surgical invasion, and discomfort for the patient. Since it is known that endothelialization can also occur from circulating EPCs, we hypothesized that perfusion with blood followed by perfusion with endothelial medium will be sufficient for recellularization. The safety of vein tissues engineered using a similar method is seen from successful results of transplantation when two such veins were implanted into children with extra hepatic portal vein obstruction 7 . We speculate that the growth factors in decellularized extracellular matrix will permit the attachment of circulating EPCs from blood 24 . Recellularization of veins following a similar protocol showed cells positive for VEGF receptor-2 and cluster of differentiation (CD) 14 on the lumen while CD45 expressing cells were seen in adventitia 7 . We also imagine that a continuous endothelial layer may not be observed in all cases especially when using blood from older and diseased patients as it is known that such individuals have decreased numbers of circulating progenitor cells 25 . However, we postulate that perfusion with the recipient's own blood may mask many of the antigens that are exposed because of decellularization and may thus decrease the chances of adverse inflammatory reactions when transplanted as opposed to transplanting only decellularized blood vessels. In addition, blood perfusion can deposit increased levels of growth factors on the lumen and adventitia which in turn may recruit increased numbers of circulating progenitor cells resulting in a rapid process of recellularization in vivo.
The advantages of the bioreactor design used in this study are complete autoclaving, easy assembly, cost-effectiveness, easy handling and the least possibility of damage. In our experience, using the current design, veins up to 10 cm in length were recellularized. Even though veins up to 25 cm in length can also be recellularized by keeping the vein in "U" shape inside the bioreactor, this should be validated. The bioreactor design shows that the direction of flow in the vein is against gravity and is designed as such because it is the normal direction of flow for these veins in humans. The 12 h perfusion of the endothelial medium step is to precondition the vein and increase the affinity for attachment of incoming EPCs. Addition of extra heparin and perfusion for 1 h will lower the risk of forming blood clots in the tubes during blood perfusion.
The volume of blood required is dependent on the length of the vein. The basic principle we follow for blood volume is that the vein should be submerged in blood. While handling blood volumes larger than 45 mL, occasional mixing might be required to prevent cell accumulation in the bottom of the bioreactor. We added Steen's solution to blood since it contains a high amount of proteins and components required to maintain tissues healthy during organ transplantation 26, 27 . Addition of VEGF and b-FGF is beneficial as they are potent angiogenic growth factors 28 and their presence induces migration, proliferation, and differentiation of EPCs 29, 30, 31, 32 . The amount of VEGF added is based on our previous unpublished results where the proliferation of EPCs was seen at 80 ng/mL. Addition of aspirin inhibits the activation of platelets 33 thereby decreasing the chances of their attachment to endothelial layer. Continuous monitoring and addition of glucose will also be beneficial for cell proliferation and preventing hemolysis of red blood cells.
Since only a simple blood sample is required from the recipient, it can be considered as an easy and feasible procedure requiring less technical expertise. Even though, the whole procedure shown here from start to finish takes 20 days, storing the decellularized veins as an off the shelf product will shorten the procedure to 8 days for patients. Although storage of decellularized veins technically should not affect the recellularization efficiency, it must be evaluated. Tissue-engineered veins generated following this procedure can be used in the clinic for bypass surgeries, replacing obstructed veins, venous insufficiency leading to varicose veins without the need for immune suppression and thus providing a better quality of life for the patient.
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